阿西美辛叔丁基酯 | 75302-98-6

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 阿西美辛叔丁基酯
• 中文别名: 1-丙酮,1,1'-[6,7,9,10,17,18,20,21-八氢二苯并[b,k][1,4,7,10,13,16]六噁环十八英-2,13(或2,14)-二基]二[2-甲基-(9CI)
• 英文名称: acemetacin tert-butyl ester
• 英文别名: ((tert-Butyl)oxycarbonyl)methyl 2-(1-((4-chlorophenyl)carbonyl)-5-methoxy-2-methylindol-3-yl)acetate；2-tert-Butoxy-2-oxoethyl [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetate；[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl] 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate
• CAS: 75302-98-6
• 化学式: C₂₅H₂₆ClNO₆
• 分子量: 471.938
• InChiKey: FPYWWHOBBPHPFR-UHFFFAOYSA-N

物化性质

• LogP：
  5.78

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  83.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  阿西美辛叔丁基酯 在 盐酸 、 乙酸酐 作用下， 以 溶剂黄146 为溶剂， 反应 5.0h， 以99.45%的产率得到阿西美辛
  参考文献：
  名称：

  一种阿西美辛的制备方法

  摘要：

  一种阿西美辛的制备方法，包括以下步骤：步骤（1）：在冰醋酸内通入氯化氢制备氯化氢的醋酸溶液；步骤（2）：向步骤1制得的氯化氢的醋酸溶液中加入醋酸酐；步骤（3）：向将步骤2得的氯化氢‑醋酸‑醋酸酐混合酸解溶液中加入阿西美辛叔丁酯后恒温搅拌；步骤（4）：反应完毕后降温、静置结晶、过滤、顶洗得到粗品阿西美辛；步骤（5）：粗品阿西美辛精制得到成品阿西美辛。本发明提供了一种阿西美辛的制备方法，可以在采用现有设备的前提下，去除原材料中水份对阿西美辛叔丁酯酸解反应的影响，提高产品收率，降低生产成本，提高经济效益。

  公开号：

  CN111960986A
• 作为产物：
  描述：

  氯乙酸叔丁酯 、 吲哚美辛 在 苄基三乙基氯化铵 、 sodium carbonate 作用下， 以 甲苯 为溶剂， 反应 45.0h， 以95.7%的产率得到阿西美辛叔丁基酯
  参考文献：
  名称：

  一种阿西美辛的制备方法

  摘要：

  一种阿西美辛的制备方法，包括以下步骤：步骤（1）：在冰醋酸内通入氯化氢制备氯化氢的醋酸溶液；步骤（2）：向步骤1制得的氯化氢的醋酸溶液中加入醋酸酐；步骤（3）：向将步骤2得的氯化氢‑醋酸‑醋酸酐混合酸解溶液中加入阿西美辛叔丁酯后恒温搅拌；步骤（4）：反应完毕后降温、静置结晶、过滤、顶洗得到粗品阿西美辛；步骤（5）：粗品阿西美辛精制得到成品阿西美辛。本发明提供了一种阿西美辛的制备方法，可以在采用现有设备的前提下，去除原材料中水份对阿西美辛叔丁酯酸解反应的影响，提高产品收率，降低生产成本，提高经济效益。

  公开号：

  CN111960986A

文献信息

• Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications
  申请人：NitroMed, Inc.

  公开号：US20040024057A1

  公开（公告）日：2004-02-05

  The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

  该发明描述了新型亚硝化非甾体抗炎药（NSAIDs）及其药用盐，以及包含至少一种亚硝化NSAID的新型组合物，以及可选地，至少一种提供、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮源性舒张因子水平或是一氧化氮合酶底物的化合物，和/或至少一种治疗剂。该发明还提供了包含至少一种亚硝化NSAID和至少一种提供、转移或释放一氧化氮、提高内源性内皮源性舒张因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂的新型组合物。该发明还提供了包含至少一种亚硝化NSAID，可选地至少一种一氧化氮供体和/或至少一种治疗剂的新型试剂盒。该发明还提供了治疗炎症、疼痛和发热的方法；治疗胃肠道疾病的方法；促进伤口愈合的方法；治疗和/或预防由非甾体抗炎化合物使用引起的胃肠道、肾脏和/或呼吸道毒性的方法；治疗炎症性疾病状态和/或疾病的方法；以及治疗和/或预防眼科疾病和/或疾病的方法。
• Chemoselective ester/ether C–O cleavage of methyl anisates by aluminum triiodide
  作者：Dayong Sang、Cuicui Yi、Zhoujun He、Jiahui Wang、Juan Tian、Ming Yao、Hong Shi

  DOI：10.1016/j.tetlet.2018.03.010

  日期：2018.4

  mediated chemoselective ester/ether C–O cleavage of methyl anisates was investigated. o-Anisate undergoes ether cleavage at low temperatures in carbon disulfide, cyclohexane and acetonitrile. Further cleavage of the ester group occurs at elevated temperatures to afford salicylic acid. The cleavage of p-anisate is solvent-dependent. In cyclohexane, the ester and ether groups were cleaved non-selectively

  研究了由三碘化铝介导的甲基茴香酸酯的化学选择性酯/醚的C-O裂解。邻氨基苯甲酸在低温下在二硫化碳，环己烷和乙腈中进行醚裂解。酯基团的进一步裂解在升高的温度下发生，以提供水杨酸。对茴香酸酯的裂解是溶剂依赖性的。在环己烷，酯和醚基团分别切割非选择性地得到等摩尔量的p -anisic酸与甲基p-羟基苯甲酸酯。与醚基在二硫化碳中的裂解相比，酯基在乙腈中的裂解优先。使用吡啶作为除酸剂可以改善酯的裂解反应。探究了茴香酸酯对AlI 3的对比反应性的原因，并将该方法用于裂解醋乙酰胺的叔丁酯，在这些条件下得到了不同的产物。
• Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
  申请人：Earl A. Richard

  公开号：US20050222243A1

  公开（公告）日：2005-10-06

  The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

  本发明描述了新型亚硝基化非甾体抗炎药（NSAIDs）及其药学上可接受的盐，以及包含至少一种亚硝基化NSAID和可选地至少一种化合物的新型组合物，该化合物捐赠、转移或释放一氧化氮，刺激内源性一氧化氮的合成，提高内源性的内皮源性舒张因子水平或是一氧化氮合酶的底物，和/或至少一种治疗剂。本发明还提供了包含至少一种亚硝基化NSAID和至少一种化合物的新型组合物，该化合物捐赠、转移或释放一氧化氮，提高内源性的内皮源性舒张因子水平，刺激内源性一氧化氮的合成或是一氧化氮合酶的底物和/或至少一种治疗剂。本发明还提供了包含至少一种亚硝基化NSAID、可选地至少一种一氧化氮供体和/或至少一种治疗剂的新型试剂盒。本发明还提供了治疗炎症、疼痛和发热的方法；治疗胃肠道疾病的方法；促进伤口愈合的方法；治疗和/或预防由非甾体抗炎化合物使用引起的胃肠道、肾脏和/或呼吸毒性的方法；治疗炎症性疾病状态和/或疾病的方法；以及治疗和/或预防眼科疾病和/或疾病的方法。
• NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：EARL Richard A.

  公开号：US20100093671A1

  公开（公告）日：2010-04-15

  The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

  该发明描述了新型亚硝酰化非甾体抗炎药（NSAIDs）及其药学上可接受的盐，并且描述了至少包含一种亚硝酰化NSAID和可选的至少一种化合物的新型组合物，该化合物捐赠、转移或释放一氧化氮，刺激内源性一氧化氮的合成，提高内源性内皮源性松弛因子的水平或是一氧化氮合酶的底物，并/或至少包含一种治疗剂。该发明还提供了至少包含一种亚硝酰化NSAID和至少一种化合物的新型组合物，该化合物捐赠、转移或释放一氧化氮，提高内源性内皮源性松弛因子的水平，刺激内源性一氧化氮的合成或是一氧化氮合酶的底物，并/或至少包含一种治疗剂。该发明还提供了至少包含一种亚硝酰化NSAID，可选的至少一种一氧化氮供体和/或至少一种治疗剂的新型试剂盒。该发明还提供了治疗炎症、疼痛和发热的方法；治疗胃肠道疾病的方法；促进伤口愈合的方法；治疗和/或预防使用非甾体抗炎化合物导致的胃肠道、肾脏和/或呼吸道毒性的方法；治疗炎症性疾病状态和/或疾病的方法；以及治疗和/或预防眼科疾病和/或疾病的方法。
• Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use
  申请人：Earl Richard

  公开号：US20110098253A1

  公开（公告）日：2011-04-28

  The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders comprising administration of novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent.

  该发明还提供了治疗炎症、疼痛和发热的方法；治疗胃肠道疾病的方法；促进伤口愈合的方法；治疗和/或预防非甾体类抗炎化合物使用引起的胃肠道、肾脏和/或呼吸道毒性的方法；治疗炎症性疾病状态和/或疾病的方法；以及治疗和/或预防眼科疾病和/或疾病的新组合物的给药方法，该组合物包括至少一种硝化的非甾体类抗炎药，以及可选地至少一种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂。